Gilead reported mid-stage results for emvistegrast, an oral therapy for ulcerative colitis, showing symptom elimination in a Phase 2 dose-finding trial. The company said a 200 mg daily regimen for 12 weeks produced a 23% placebo-adjusted clinical remission rate. The reported efficacy outperformed analyst expectations and is being framed by Gilead as a potential best-in-class oral option in a space where multiple mechanisms are competing to improve durable remission. The trial data were shared ahead of further development steps that will determine whether the program can translate into late-stage success. The readout adds to competitive pressure in oral inflammatory bowel disease (IBD) drug development, where endpoints, durability, and patient subgroups often determine differentiation in later trials. Gilead’s next phase of work will likely focus on confirming the remission signal across broader patient populations and aligning the safety profile with the dosing intensity required for maintenance goals.